General
Preferred name
MK-571
Synonyms
L660711 ()
L-660711 ()
MK571 sodium ()
L-660711 sodium salt ()
L-660711 (sodium salt) ()
MK-571 sodium salt ()
Verlukast sodium ()
MK 571 ()
L-660711 (sodium salt)MK-571 sodium salt ()
L-660771 ()
PCA 4248 ()
MK-571 (sodium) ()
L-660711 (sodium) ()
L-660711, L660711, MK-571, MK 571 ()
verlukast ()
MK571 ()
MK-571 sodium ()
MK 571 (sodium salt) ()
P&D ID
PD021498
CAS
115104-28-4
115103-85-0
120443-16-5
Tags
available
drug candidate
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release[1][2][3].
PRICE 81
DESCRIPTION MK-571 sodium (L-660711 sodium salt) is a selective, orally active antagonist of the CysLT1 receptor. MK-571 sodium is a multidrug resistance protein-2 (ABCC2, Mrp2) inhibitor used to demonstrate the role of Mrp2 in the cellular efflux of drugs, xenobiotics, and their conjugates. MK-571 sodium can inhibit the synthesis of K-4??-O-GlcA (19.7 ??M). MK571 dose-dependently inhibits the intracellular biosynthesis of all flavonol sulphates and glucuronides by Caco-2 cells. MK-571 sodium significantly inhibits phase-2 conjugation of kaempferol by cell-free extracts of Caco-2, and production of kaempferol-4??-O-glucuronide was competitively inhibited. In addition to inhibiting MRP2, MK571 is a potent inhibitor of enterocyte phase-2 conjugation.
DESCRIPTION MK-571 is a stereo enantiomer of . Be aware of the confusion caused by incorrectly using MK-571 as a synonym for verlukast that has arisen in online resources. (GtoPdb)
DESCRIPTION MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release[1][2][3].
PRICE 79
DESCRIPTION The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1. (BOC Sciences Bioactive Compounds)
DESCRIPTION MK-571 sodium (L-660711 sodium salt) is a selective, orally active antagonist of the CysLT1 receptor. MK-571 sodium is a multidrug resistance protein-2 (ABCC2, Mrp2) inhibitor used to demonstrate the role of Mrp2 in the cellular efflux of drugs, xenobiotics, and their conjugates. MK-571 sodium can inhibit the synthesis of K-4′-O-GlcA (19.7 μM). MK571 dose-dependently inhibits the intracellular biosynthesis of all flavonol sulphates and glucuronides by Caco-2 cells. MK-571 sodium significantly inhibits phase-2 conjugation of kaempferol by cell-free extracts of Caco-2, and production of kaempferol-4′-O-glucuronide was competitively inhibited. In addition to inhibiting MRP2, MK571 is a potent inhibitor of enterocyte phase-2 conjugation. (TargetMol Bioactive Compound Library)
DESCRIPTION Potent PAF receptor antagonist (Tocris Bioactive Compound Library)
DESCRIPTION MK-571 is a CysLT1 receptor antagonist. It can be used for the treatment of respiratory diseases. (BOC Sciences Bioactive Compounds)
DESCRIPTION MK 571 (L660711) is an orally active antagonist of CysLT1 receptor. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
0
Compound Sets
16
AdooQ Bioactive Compound Library
A12529
BOC Sciences Bioactive Compounds
mk-571-sodium-salt-cas-115103-85-0-359442
mk-571-cas-115104-28-4-item-195897
Cayman Chemical Bioactives
70720
10029
Concise Guide to Pharmacology 2019/20
10346
Concise Guide to Pharmacology 2021/22
10346
Concise Guide to Pharmacology 2023/24
10346
CZ-OPENSCREEN Bioactive Library
DrugMAP
DMG5VJF
EU-OPENSCREEN Bioactive Compound Library
EOS101140
Guide to Pharmacology
10346
MedChem Express Bioactive Compound Library
HY-19989A
HY-19989
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
mk571
TargetMol Bioactive Compound Library
T3148
T7841
Tocris Bioactive Compound Library
2338
External IDs
42
Properties
(calculated by RDKit )
Molecular Weight
514.12
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
11
Ring Count
3
Aromatic Ring Count
3
cLogP
6.48
TPSA
70.5
Fraction CSP3
0.27
Chiral centers
1.0
Largest ring
6.0
QED
0.3
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CysLTR1
Leukotriene Receptor
LPL Receptor
P-glycoprotein
LTR
Primary Target
Leukotriene and Related Receptors
MOA
Inverse Agonist
Leukotriene CysLT1 (LTD4) Antagonists
Leukotriene Synthesis Inhibitors
Member status
member
Pathway
Immunology/Inflammation
GPCR/G protein
Membrane Transporter/Ion Channel
Solubility
DMSO: ≥ 33 mg/mL
Source data